Life Sciences

BullFrog AI advances neuropsychiatric drug discovery

BullFrog AI reported that its platform identified and prioritized novel major-depressive-disorder targets from proprietary neuropsychiatric multi-omic data for an unnamed top-five pharmaceutical company.

BullFrog AI announced progress in a commercial project with a top-five global pharmaceutical company focused on major depressive disorder. According to the source, its AI and machine-learning platform analyzed proprietary neuropsychiatric multi-omic datasets to identify and prioritize novel therapeutic targets. The company describes its platform as combining data harmonization, causal analytics, patient-subgroup discovery, and auditable decision support. The announcement is significant because it illustrates the use of multi-omic data and causal AI in neuropsychiatric drug discovery. The available source does not name the pharmaceutical partner, disclose the targets, or provide clinical validation results.

Original source: GlobeNewswire

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI